Sorafenib in metastatic uveal melanoma: efficacy, toxicity and health-related quality of life in a multicentre phase II study

被引：0
|
作者：
F Mouriaux
V Servois
J J Parienti
T Lesimple
A Thyss
C Dutriaux
E M Neidhart-Berard
N Penel
C Delcambre
L Peyro Saint Paul
A D Pham
N Heutte
S Piperno-Neumann
F Joly
机构：
[1] CHU Rennes,Service d’ophtalmologie (Department of Ophthalmology)
[2] Faculté de Médecine (Faculty of Medicine),Département d’Imagerie Médicale (Curie Institute, Department of Medical Imaging)
[3] Université de Rennes 1,Service Dermatologie (Dermatology Department)
[4] Centre universitaire d’ophtalmologie-Recherche (Ophthalmology-Research University Centre),Département d’Oncologie Médicale, (Department of Medical Oncology
[5] Hôpital du Saint-Sacrement,undefined
[6] Centre de Recherche du CHU de Québec (CHU Quebec Research Centre),undefined
[7] CHU Caen,undefined
[8] Institut Curie,undefined
[9] Centre Eugène Marquis,undefined
[10] Centre Antoine Lacassagne,undefined
[11] CHU de Bordeaux,undefined
[12] Centre Léon Bérard,undefined
[13] Centre Oscar Lambret,undefined
[14] Centre François Baclesse,undefined
[15] Institut Curie,undefined
[16] Curie Institute),undefined
来源：
British Journal of Cancer | 2016年 / 115卷
关键词：
uveal; melanoma; eye metastasis; targeted therapy; quality of life; survival;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：20 / 24
页数：4
相关论文
共 50 条
  • [1] Sorafenib in metastatic uveal melanoma: efficacy, toxicity and health-related quality of life in a multicentre phase II study
    Mouriaux, F.
    Servois, V.
    Parienti, J. J.
    Lesimple, T.
    Thyss, A.
    Dutriaux, C.
    Neidhart-Berard, E. M.
    Penel, N.
    Delcambre, C.
    Saint Paul, L. Peyro
    Pham, A. D.
    Heutte, N.
    Piperno-Neumann, S.
    Joly, F.
    BRITISH JOURNAL OF CANCER, 2016, 115 (01) : 20 - 24
  • [2] Sorafenib in metastatic uveal melanoma : A multicentric prospective phase II study
    Mouriaux, Frederic
    Servois, Vincent
    Piperno-Neumann, Sophie
    Lesimple, Thierry
    Thyss, Antoine
    Jouary, Thomas
    Neidhart-Berard, Eve-Marie
    Penel, Nicolas
    Delcambre, Corinne
    Joly, Francoise
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2015, 56 (07)
  • [3] Health-Related Quality of Life and Sorafenib
    Spinzi, Giancarlo
    Terreni, Natalia
    HEPATOLOGY, 2010, 52 (04) : 1523 - 1523
  • [4] What matters most to people with metastatic uveal melanoma? A qualitative study to inform future measurement of health-related quality of life
    Ng, Carrie-Anne
    Luckett, Tim
    Mulhern, Brendan
    Kee, Damien
    Lai-Kwon, Julia
    Joshua, Anthony M.
    MELANOMA RESEARCH, 2024, 34 (03) : 248 - 257
  • [5] Health-related quality of life among patients with metastatic melanoma: results from an international phase 2 multicenter study
    Robinson, Donald W., Jr.
    Cormier, Janice N.
    Zhao, Ning
    Uhlar, Clarissa M.
    Revicki, Dennis A.
    Cella, David
    MELANOMA RESEARCH, 2012, 22 (01) : 54 - 62
  • [6] A MULTICENTRE, PHASE II STUDY OF CP-4055 IN COMBINATION WITH SORAFENIB IN PATIENTS WITH METASTATIC MALIGNANT MELANOMA
    Dueland, S.
    Aamdal, S.
    Nyakas, M.
    Lundgren, L.
    Wagenius, G.
    Ljuslinder, I.
    Stierner, U.
    Gaullier, J.
    Nilsson, B. I.
    Rasch, W.
    ANNALS OF ONCOLOGY, 2008, 19 : 245 - 246
  • [7] A Phase II Study of Glembatumumab Vedotin for Metastatic Uveal Melanoma
    Hasanov, Merve
    Rioth, Matthew J.
    Kendra, Kari
    Hernandez-Aya, Leonel
    Joseph, Richard W.
    Williamson, Stephen
    Chandra, Sunandana
    Shirai, Keisuke
    Turner, Christopher D.
    Lewis, Karl
    Crowley, Elizabeth
    Moscow, Jeffrey
    Carter, Brett
    Patel, Sapna
    CANCERS, 2020, 12 (08) : 1 - 12
  • [8] A phase II study of nivolumab/relatlimab in metastatic uveal melanoma
    Lutzky, J.
    Hernandez-Aya, L.
    Feun, L.
    Correa, Z.
    King, J.
    Estevez, C.
    Decatur, C.
    Dollar, J. J.
    Reis, I.
    Harbour, J. W.
    ANNALS OF ONCOLOGY, 2024, 35 : S741 - S741
  • [9] Health-related quality of life in patients with advanced metastatic melanoma: Results of a randomized phase III study comparing temozolomide with dacarbazine
    Kiebert, GM
    Jonas, DL
    Middleton, MR
    CANCER INVESTIGATION, 2003, 21 (06) : 821 - 829
  • [10] Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer
    Efficace, F
    Biganzoli, L
    Piccart, M
    Coens, C
    Van Steen, K
    Cufer, T
    Coleman, RE
    Calvert, HA
    Gamucci, T
    Twelves, C
    Fargeot, P
    Bottomley, A
    EUROPEAN JOURNAL OF CANCER, 2004, 40 (07) : 1021 - 1030
12345